Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, probe trial to evaluate whether, at comparable blood pressure control, combined therapy with ACEI BEN and ARB VAL reduces progression to ESRD more effectively than BEN or VAL alone in high risk patients with type 2 diabetes and overt nephropathy

Next Previous
X
Search
Trial Profile

A prospective, randomized, probe trial to evaluate whether, at comparable blood pressure control, combined therapy with ACEI BEN and ARB VAL reduces progression to ESRD more effectively than BEN or VAL alone in high risk patients with type 2 diabetes and overt nephropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valsartan (Primary) ; Benazepril
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms VALID

    • Most Recent Events

    • 15 Jul 2021 Status changed from recruiting to active, no longer recruiting to completed.
    • 26 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 May 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top